🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Decitabine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial
  2. Decitabine plus HAAG regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  3. Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  4. Deflazacort

    PTC THERAPEUTICS, INC.

    Limb-Girdle Muscular Dystrophy

    phase 3 small molecule terminated

    1 trial
  5. Delayed and extended release mesalazine

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial
  6. Depigoid Grass-Mix (1000 DPP/ml), Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, The placebo to be used in the clinical trial is the solvent used in the investigational medicinal products’ (IMPs) formulation. The resulting product is a suspension., Depigoid FORTE Grass-Mix (3000 DPP/ml)

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without controlled asthma

    phase 3 small molecule active

    1 trial
  7. Deucravacitinib placebo 3 mg film-coated tablets oral use, Deucravacitinib placebo 6 mg film-coated tablets oral use, deucravacitinib, deucravacitinib

    Bristol-Myers Squibb Australia Pty Ltd

    Sjogren's syndrome

    phase 3 small molecule active

    1 trial
  8. Dexa 8 mg inject JENAPHARM Injektionslösung, VELCADE 3.5 mg powder for solution for injection, Dexamethason 8 mg GALEN® Tabletten, Dexamethasone Tablets BP 2.0mg, Dexamethasone 2mg Tablets, Dexa-ratiopharm® 8 mg Injektionslösung, DARZALEX 20 mg/mL concentrate for solution for infusion, Dexamethason 8 mg JENAPHARM®

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  9. Dexamethason 8 mg GALEN® Tabletten, Imnovid 1 mg hard capsules, Dexamethasone 2mg Tablets, Dexamethason 8 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, Imnovid 4 mg hard capsules

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial
  10. Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m

    Celgene Europe Limited

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    phase 3 small molecule active

    1 trial
  11. Dexamethasone

    Amgen

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial
  12. Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  13. Dexlansoprazole

    Takeda

    Heartburn

    phase 3 small molecule completed

    1 trial
  14. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    2 trials
  15. Dexlansoprazole

    Takeda

    Erosive Esophagitis

    phase 3 small molecule terminated

    2 trials
  16. Dexlansoprazole MR

    Takeda

    Esophagitis, Reflux

    phase 3 small molecule completed

    5 trials
  17. Dexlansoprazole MR

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    4 trials
  18. Dexlansoprazole MR QD

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    1 trial
  19. Dexmedetomidine 100 micrograms/ml concentrate for solution for infusion, Midazolam Lek 1 mg/ml raztopina za injiciranje/infundiranje

    Tour Hekla

    Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:

    phase 3 small molecule active

    1 trial
  20. Diacomit 250 mg hard capsules, Matched Placebo will consist in caspules similar to the 250 and 500 mg capsules of stiripentol but with no active ingredient, Diacomit 500 mg hard capsules

    Biocodex

    Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)

    phase 3 small molecule active

    1 trial
  21. Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category

    Aquestive Therapeutics

    Epilepsy

    phase 3 small molecule completed

    1 trial
  22. Diflucan 200mg Hard Capsules, PLACEBO to Posaconazol hexal, Posaconazol HEXAL 100 mg, NOXAFIL® (posaconazole) Injection, Placebo to bactrim, diflucan 200 mg - microcrystalline cellulose capsules, DIFLUCAN INJECTION, REZZAYO 200 mg powder for concentrate for solution for infusion, Saline solution, REZZAYO 200 mg powder for concentrate for solution for infusion, Bactrim Tablets, NOXAFIL® (posaconazole) Delayed-Release Tablets

    Mundipharma Pty Limited

    Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)

    phase 3 small molecule active

    1 trial
  23. Dipyridamole 50mg tid

    The First People's Hospital of Lianyungang

    Restless Leg Syndrome Due to Uraemia

    phase 3 small molecule active

    1 trial
  24. Distress Thermometer and Problems List

    United Therapeutics Europe Ltd

    Cancer

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources